The Impact of Chronic Kidney Disease in Diabetic COVID-19 Patients

BACKGROUND: Steatosis has been clearly reported during alcohol intake, excess weight and viral hepatitis C. This has not been sufficiently studied in chronic hepatitis B (CHB). We aimed to determine the prevalence of steatosis during CHB treated with entecavir (ETV) and its impact on virological response. PATIENTS AND METHODS: A retrospective study, including CHB patients treated with ETV, hospitalized in an infectious diseases department between 2009 and 2019. The population was divided into G1 (with steatosis) and G2 (without steatosis). RESULTS: In total, 233 patients were collected. Themean agewas 38±10 years with a sex ratio (M/F)=2.6. The population was divided into G1 (n=43; 18.5%) and G2 (n=190; 81.5%). G1 patients were older (38 vs 35 years old, p=0.03). The presence of steatosis was not associatedwith sex (p=0.2), with diabetes (p=0.2) or alcohol consumption (p = 0.3). Thrombocytopenia was more observed in G1 (20% vs 6%, p = 0.03). Cytolysis was found in both groups (p=0.4). Cytolysis was greater than 3 times the upper limit of normal in 32.5 % of cases. The virological response was complete in both groups regardless of the presence of steatosis or not. In fact, its rate reached 79% in G1 and 80% in G2 (p = 0.6). CONCLUSION: Despite the young age of the patients and the absence of diabetes, steatosis was common. The role of hepatitis Bmay be suggested. Steatosis do not influence the progression of fibrosis or the response to therapy.